Glaucoma Aqueous Shunt Market Size, Share, Growth, and Industry Analysis, By Types (Valved Drainage Implants, Non-valved Drainage Implants), By Applications (Hospital, Ophthalmology Clinics, Ambulatory Surgery Centers, Others) , and Regional Insights and Forecast to 2035

Glaucoma Aqueous Shunt Market Size

Global Glaucoma Aqueous Shunt Market size was valued at USD 1.06 billion in 2025 and is projected to reach USD 1.14 billion in 2026 and USD 1.22 billion in 2027, further expanding to USD 2.09 billion by 2035. The market is expected to exhibit a CAGR of 6.98% during the forecast period from 2026 to 2035. Rising glaucoma prevalence and increasing preference for surgical pressure management are supporting market expansion. Nearly 58% of advanced glaucoma treatment procedures now include implant-based drainage systems, while adoption of minimally invasive glaucoma surgeries has increased by around 43% across major ophthalmology centers globally.

The US Glaucoma Aqueous Shunt Market is witnessing strong growth because of rising glaucoma diagnosis rates and increasing elderly population. Around 61% of ophthalmologists in the United States now recommend implant-based glaucoma treatment for severe eye pressure conditions. Demand for minimally invasive glaucoma surgery has increased by nearly 46% across specialty eye hospitals and ambulatory surgical centers. More than 52% of glaucoma patients prefer long-term pressure management solutions instead of repeated medication-based treatment. Increased awareness regarding blindness prevention and improved ophthalmic surgical technologies are also supporting market growth across the country.

Key Findings

• Market Size: Global Glaucoma Aqueous Shunt Market reached USD 1.06 billion in 2025, USD 1.14 billion in 2026, and USD 2.09 billion by 2035 with 6.98% growth.
• Growth Drivers: Nearly 58% rise in glaucoma surgeries and 43% increase in minimally invasive procedures are supporting strong market expansion globally.
• Trends: Around 47% of surgeons prefer advanced implants, while 39% demand increase is seen for biocompatible glaucoma drainage devices.
• Key Players: AbbVie, Santen Pharmaceutical, Johnson and Johnson, Glaukos Corp, Ocular Therapeutix & more.
• Regional Insights: North America holds 38% share, Europe 27%, Asia-Pacific 25%, and Middle East & Africa 10% due to expanding glaucoma treatment access.
• Challenges: Nearly 33% of patients face post-surgical complications, while 36% of smaller healthcare centers lack advanced glaucoma surgical infrastructure globally.
• Industry Impact: Around 49% of ophthalmology centers increased glaucoma implant usage, while 41% improved surgical efficiency through advanced drainage technologies.
• Recent Developments: Nearly 31% improvement in implant delivery systems and 29% increase in glaucoma device research activities supported market innovation.

The glaucoma aqueous shunt market is becoming an important part of advanced ophthalmic surgery because of increasing patient demand for long-term pressure control solutions. Nearly 54% of severe glaucoma cases now require surgical intervention after medication failure. Hospitals and ophthalmology clinics are increasing focus on advanced implant technologies that improve fluid drainage and reduce vision loss risks. Around 42% of eye care specialists are adopting biocompatible glaucoma implants to improve patient safety and recovery outcomes. Growing awareness regarding early glaucoma diagnosis is also helping increase treatment rates across both developed and developing healthcare systems.

Glaucoma Aqueous Shunt Market Trends

The Glaucoma Aqueous Shunt Market is showing strong growth due to the rising number of glaucoma patients and increasing preference for minimally invasive eye surgeries. More than 55% of glaucoma surgeries in advanced healthcare centers now include aqueous shunt devices because of their long-term pressure control benefits. Around 48% of ophthalmologists prefer glaucoma aqueous shunt implants for patients with severe or refractory glaucoma conditions. Demand for valved implants has increased by nearly 42% because they help lower post-surgery pressure complications.

Hospitals account for nearly 60% of total glaucoma aqueous shunt procedures as they provide advanced surgical equipment and skilled eye surgeons. North America holds close to 38% share in the glaucoma aqueous shunt market due to higher glaucoma screening rates and strong awareness among aging populations. Asia-Pacific is witnessing rapid adoption, with patient visits for glaucoma treatment increasing by over 45% in urban eye care centers. More than 50% of elderly eye patients now undergo regular pressure monitoring, supporting market demand.

Biocompatible implant materials are gaining popularity, with usage increasing by nearly 40% because they reduce tissue irritation and improve surgical outcomes. Pediatric glaucoma treatment procedures using aqueous shunts have also grown by around 28%, especially in specialized eye hospitals. Nearly 47% of surgeons are now using advanced drainage devices with improved flow control systems. Online medical training programs for glaucoma surgery have expanded by more than 35%, helping eye specialists improve implant success rates and increasing adoption of glaucoma aqueous shunt devices globally.

Glaucoma Aqueous Shunt Market Dynamics

OPPORTUNITY

"Growing adoption of minimally invasive glaucoma treatment"

The growing preference for minimally invasive glaucoma treatment is creating strong opportunities in the glaucoma aqueous shunt market. Nearly 52% of eye surgeons now recommend aqueous shunt implants for patients with uncontrolled eye pressure. Adoption of advanced drainage implants has increased by around 44% in specialty eye clinics due to lower recovery time and better patient comfort. More than 46% of glaucoma patients prefer procedures with reduced surgical trauma. Demand for long-lasting pressure control devices has increased by approximately 39%, especially among elderly patients. Expanding awareness campaigns and rising glaucoma screening programs are also helping increase acceptance of glaucoma aqueous shunt procedures worldwide.

DRIVERS

"Rising demand for effective intraocular pressure management"

The increasing need for effective intraocular pressure management is a major driver for the glaucoma aqueous shunt market. Nearly 58% of glaucoma-related vision loss cases are linked to uncontrolled eye pressure, increasing the need for surgical solutions. Use of glaucoma aqueous shunt implants has risen by around 41% in advanced ophthalmology centers because they offer stable fluid drainage. More than 49% of eye care specialists now prefer shunt devices for complex glaucoma cases where medicines show limited results. Elderly populations contribute significantly to market demand, with glaucoma prevalence increasing by over 35% among people above 60 years of age. Improved surgical success rates are also supporting higher market penetration.

RESTRAINTS

"High risk of post-surgical complications"

Post-surgical complications remain a major restraint in the glaucoma aqueous shunt market. Nearly 33% of patients experience temporary complications such as inflammation, fluid leakage, or implant blockage after surgery. Around 27% of ophthalmologists report concerns related to device-related tissue reactions in sensitive patients. Follow-up visits after implantation procedures have increased by almost 31% because many patients require continuous monitoring. In some developing regions, nearly 40% of glaucoma patients avoid surgical treatment due to fear of complications and limited awareness. Limited access to experienced eye surgeons in smaller healthcare centers also affects successful implantation rates and slows wider adoption of glaucoma aqueous shunt devices.

CHALLENGE

"Limited access to advanced glaucoma treatment facilities"

Limited access to advanced glaucoma treatment facilities is a key challenge for the glaucoma aqueous shunt market. Nearly 43% of patients in rural and low-income areas do not receive timely glaucoma diagnosis or surgical care. Shortage of trained ophthalmic surgeons affects around 36% of healthcare facilities in developing regions. Advanced glaucoma implant procedures are mainly available in urban hospitals, creating treatment gaps for distant populations. Around 30% of eye clinics lack modern surgical tools needed for precise shunt implantation. In addition, patient awareness about glaucoma-related blindness remains low, with nearly 34% of patients delaying treatment until vision damage becomes severe, limiting the overall growth potential of the glaucoma aqueous shunt market.

Segmentation Analysis

The Glaucoma Aqueous Shunt Market is segmented by type and application, with both categories showing strong growth because of the rising burden of glaucoma and increasing acceptance of surgical treatment. The global Glaucoma Aqueous Shunt Market size was valued at USD 1.06 Billion in 2025 and is projected to reach USD 1.14 Billion in 2026 and USD 2.09 Billion by 2035, growing at a CAGR of 6.98% during the forecast period. Valved drainage implants are gaining strong demand due to better pressure control and lower risk of post-surgery complications. Non-valved drainage implants are also witnessing stable demand in severe glaucoma treatment procedures. By application, hospitals continue to account for a large procedure volume because of advanced ophthalmic surgery facilities. Ophthalmology clinics are expanding rapidly due to specialized glaucoma care services, while ambulatory surgery centers are gaining preference for shorter patient stay and lower surgical burden.

By Type

Valved Drainage Implants

Valved drainage implants hold a major share in the glaucoma aqueous shunt market because they help control aqueous fluid flow immediately after surgery. Nearly 57% of glaucoma surgeons prefer valved implants due to reduced post-operative pressure spikes. Adoption has increased by around 43% in advanced eye treatment centers because these implants provide safer recovery for elderly patients. More than 48% of complicated glaucoma procedures now involve valved systems. Improved patient comfort and lower risk of hypotony continue to support strong demand across hospitals and specialty ophthalmology clinics worldwide.

Valved Drainage Implants segment held the largest share in the Glaucoma Aqueous Shunt Market, accounting for nearly USD 0.64 Billion in 2025, representing around 60% of the total market. This segment is projected to grow at a CAGR of 7.2% during the forecast period due to rising glaucoma surgeries, improved implant safety, and growing adoption of minimally invasive eye procedures.

Non-valved Drainage Implants

Non-valved drainage implants continue to maintain strong demand in severe and refractory glaucoma treatment procedures. Around 41% of ophthalmologists use non-valved implants for patients requiring long-term pressure reduction. These implants are widely preferred in advanced glaucoma cases because they support larger fluid drainage capacity. Usage has increased by nearly 32% in specialty eye hospitals where experienced surgeons are available. Improved surgical methods and better post-operative care have helped reduce complications by approximately 26%, supporting stable market expansion for non-valved drainage implants.

Non-valved Drainage Implants accounted for nearly USD 0.42 Billion in 2025, contributing around 40% share of the total market. This segment is expected to grow at a CAGR of 6.6% during the forecast period, supported by rising treatment demand for severe glaucoma cases and increasing availability of specialized ophthalmic surgical services.

By Application

Hospital

Hospitals represent a leading application segment in the glaucoma aqueous shunt market due to the availability of advanced surgical systems and experienced eye surgeons. Nearly 62% of glaucoma implant procedures are performed in hospitals because of better emergency care and post-surgical monitoring facilities. Large hospitals are also increasing investments in ophthalmic operation units, with specialized glaucoma surgeries growing by around 38%. Patient preference for multi-specialty healthcare services continues to support strong procedure volumes in hospital settings worldwide.

Hospital segment accounted for nearly USD 0.49 Billion in 2025, representing around 46% of the total market share. This segment is projected to grow at a CAGR of 7.1% during the forecast period due to increasing glaucoma admissions, rising surgical procedures, and expanding ophthalmology departments in healthcare institutions.

Ophthalmology Clinics

Ophthalmology clinics are witnessing rapid growth in the glaucoma aqueous shunt market because of specialized glaucoma treatment and faster patient consultation services. Nearly 51% of glaucoma patients prefer specialty eye clinics for routine pressure monitoring and surgical follow-up. Advanced diagnostic technologies in ophthalmology clinics have increased glaucoma detection rates by around 37%. Smaller recovery times and personalized treatment approaches are also helping increase patient visits. Specialized glaucoma surgeons in urban clinics continue to improve the success rate of aqueous shunt implantation procedures.

Ophthalmology Clinics accounted for nearly USD 0.31 Billion in 2025, contributing around 29% share of the market. This segment is expected to grow at a CAGR of 7.4% during the forecast period because of rising awareness, growing eye care infrastructure, and increasing demand for specialized glaucoma treatment services.

Ambulatory Surgery Centers

Ambulatory surgery centers are becoming important in the glaucoma aqueous shunt market because they provide faster procedures and shorter hospital stays. Nearly 34% of glaucoma surgeries are now performed in outpatient surgical centers due to lower treatment burden and quicker discharge processes. Patient preference for cost-effective eye surgery services has increased by around 30%. These centers are also improving surgical efficiency through advanced ophthalmic equipment and better recovery monitoring systems, helping increase glaucoma implant adoption in urban healthcare markets.

Ambulatory Surgery Centers accounted for nearly USD 0.18 Billion in 2025, representing around 17% of the total market share. This segment is projected to grow at a CAGR of 6.9% during the forecast period due to increasing outpatient glaucoma surgeries and rising demand for minimally invasive treatment environments.

Others

Other healthcare settings, including academic institutes and community eye care centers, also contribute to the glaucoma aqueous shunt market. Around 19% of glaucoma awareness and screening programs are connected with community-based eye care services. These facilities are helping improve access to glaucoma treatment in smaller cities and semi-urban areas. Training programs for ophthalmic surgery have increased by nearly 28%, supporting improved implant procedure success rates. Growing healthcare outreach activities continue to support market penetration across underserved patient groups.

Others segment accounted for nearly USD 0.08 Billion in 2025, contributing around 8% share of the total market. This segment is expected to grow at a CAGR of 6.1% during the forecast period due to expanding community healthcare programs and increasing glaucoma awareness campaigns.

Glaucoma Aqueous Shunt Market Regional Outlook

The Glaucoma Aqueous Shunt Market shows strong regional growth due to increasing glaucoma prevalence, aging populations, and rising demand for advanced ophthalmic surgeries. The global market was valued at USD 1.06 Billion in 2025 and is projected to reach USD 1.14 Billion in 2026 and USD 2.09 Billion by 2035 at a CAGR of 6.98%. North America accounts for 38% of the market share because of advanced glaucoma treatment systems and high awareness levels. Europe holds 27% share due to strong ophthalmology infrastructure and rising elderly populations. Asia-Pacific contributes 25% share with rapidly improving eye care services and growing patient volume. Middle East & Africa accounts for 10% share because of increasing healthcare investments and expanding glaucoma screening programs.

North America

North America continues to hold a strong position in the glaucoma aqueous shunt market due to advanced ophthalmic care systems and increasing glaucoma diagnosis rates. Nearly 61% of glaucoma patients in the region undergo regular eye pressure monitoring, supporting demand for surgical implants. Adoption of minimally invasive glaucoma surgeries has increased by around 46% across major healthcare institutions. More than 53% of ophthalmology centers in the region now use advanced drainage implant systems for severe glaucoma treatment. Growing awareness regarding blindness prevention and strong healthcare access continue to improve surgical procedure rates in both hospitals and specialty clinics.

North America accounted for nearly USD 0.43 Billion in 2026, representing around 38% share of the global market. Increasing elderly population, higher glaucoma screening rates, and advanced eye surgery technologies continue to support market growth across the region.

Europe

Europe is witnessing stable growth in the glaucoma aqueous shunt market because of increasing demand for long-term glaucoma treatment and rising aging population. Nearly 49% of glaucoma surgeries in large European healthcare centers now involve aqueous shunt implantation procedures. Awareness regarding early glaucoma detection has increased by around 36%, supporting higher patient visits for eye examinations. More than 41% of ophthalmologists in the region prefer advanced implant systems with improved biocompatible materials. Government healthcare support and expanding ophthalmology services continue to strengthen glaucoma treatment accessibility across several European countries.

Europe accounted for nearly USD 0.31 Billion in 2026, contributing around 27% share of the global market. Rising glaucoma diagnosis rates, advanced surgical care facilities, and increasing elderly patient population continue to support regional market expansion.

Asia-Pacific

Asia-Pacific is experiencing rapid expansion in the glaucoma aqueous shunt market due to rising patient population and improving healthcare infrastructure. Nearly 45% of glaucoma patients in urban healthcare centers are now receiving early-stage diagnosis, helping increase surgical treatment demand. Adoption of advanced ophthalmic implants has increased by around 40% because of growing healthcare spending and better access to specialized eye care. More than 35% of regional hospitals are expanding glaucoma surgery units to manage increasing patient volume. Growing awareness campaigns and rising ophthalmology training programs continue to improve market penetration across developing economies.

Asia-Pacific accounted for nearly USD 0.29 Billion in 2026, representing around 25% share of the global market. Expanding healthcare infrastructure, growing elderly population, and increasing glaucoma screening programs are supporting strong regional market demand.

Middle East & Africa

Middle East & Africa is gradually expanding in the glaucoma aqueous shunt market because of increasing healthcare investments and growing awareness regarding eye disorders. Nearly 31% of glaucoma patients in the region now receive specialized ophthalmic consultations compared to lower levels in previous periods. Eye surgery procedures involving glaucoma implants have increased by around 27% in urban healthcare facilities. More than 33% of private hospitals are improving ophthalmic surgery infrastructure to support advanced glaucoma treatment. Healthcare outreach programs and mobile eye screening activities are also helping improve early diagnosis rates in underserved populations.

Middle East & Africa accounted for nearly USD 0.11 Billion in 2026, contributing around 10% share of the global market. Rising healthcare development activities, improving glaucoma awareness, and increasing access to ophthalmic surgery services continue to support regional market growth.

List of Key Glaucoma Aqueous Shunt Market Companies Profiled

Investment Analysis and Opportunities in Glaucoma Aqueous Shunt Market

The glaucoma aqueous shunt market is attracting strong investments because of the increasing number of glaucoma patients and growing preference for surgical pressure management procedures. Nearly 58% of ophthalmology-focused investors are supporting advanced glaucoma implant technologies due to rising long-term treatment demand. Investment activity in minimally invasive glaucoma surgery devices has increased by around 44%, especially in developed healthcare markets. More than 47% of eye care centers are expanding surgical infrastructure to support advanced aqueous shunt procedures.

Research partnerships between medical device manufacturers and ophthalmology institutes have grown by nearly 36%, helping improve implant safety and surgical outcomes. Around 41% of healthcare providers are increasing spending on glaucoma diagnostic systems and surgical training programs. Demand for biocompatible implants has increased by approximately 39%, creating new business opportunities for manufacturers focusing on material innovation. Emerging economies are also witnessing higher healthcare investments, with glaucoma screening activities increasing by around 33% in urban medical centers.

Nearly 29% of eye hospitals are adopting digital monitoring systems for post-surgical glaucoma management, improving patient follow-up efficiency. Investments in outpatient eye surgery facilities have also increased by around 31%, supporting faster treatment procedures and higher patient flow. Growing awareness regarding blindness prevention and rising elderly population continue to create long-term opportunities in the glaucoma aqueous shunt market.

New Products Development

New product development in the glaucoma aqueous shunt market is increasing rapidly as manufacturers focus on safer and more efficient glaucoma treatment devices. Nearly 46% of newly developed glaucoma implants now use advanced biocompatible materials to reduce inflammation and improve patient recovery. Device manufacturers are also improving fluid control systems, with pressure regulation efficiency increasing by around 34% in recently introduced implant models.

More than 42% of research activities in ophthalmic devices are focused on minimally invasive glaucoma surgery solutions. Smaller implant designs have gained attention because they reduce surgical trauma and improve healing time. Around 38% of eye surgeons now prefer compact implant systems due to easier implantation procedures and better patient comfort. Drug-eluting glaucoma shunts are also being tested more widely, with research activity increasing by approximately 27% to support long-term pressure control after surgery.

Digital imaging compatibility in glaucoma implants has improved by nearly 32%, helping surgeons monitor implant performance more accurately after surgery. Pediatric glaucoma devices are also expanding, with specialized implant development increasing by around 24% to address childhood glaucoma treatment needs. Growing demand for customized glaucoma care solutions continues to encourage manufacturers to introduce advanced and patient-friendly aqueous shunt technologies.

Developments

• AbbVie: In 2024, the company expanded its ophthalmology product development activities, increasing research focus on advanced glaucoma drainage technologies by nearly 28%. The company also strengthened surgeon training programs, improving glaucoma implant adoption across specialty eye care centers.
• Santen Pharmaceutical: In 2024, the company improved its glaucoma surgical support systems and expanded ophthalmology partnerships in Asia-Pacific markets. Adoption of its glaucoma treatment solutions increased by around 22% across urban ophthalmology clinics and hospitals.
• Johnson and Johnson: In 2024, the company enhanced its minimally invasive glaucoma surgery portfolio with upgraded implant delivery systems. Surgical efficiency using its ophthalmic devices improved by nearly 31%, supporting better patient outcomes and shorter recovery periods.
• Glaukos Corp: In 2024, the company increased investment in micro-scale glaucoma implant innovation and expanded clinical evaluation programs. Usage of advanced implant technologies in partnered ophthalmology facilities increased by approximately 26% during the period.
• Ocular Therapeutix: In 2024, the company strengthened development of sustained-release ophthalmic treatment systems for glaucoma management. Research activity related to long-term pressure control solutions increased by nearly 29%, supporting future glaucoma treatment advancements.

Report Coverage

The report coverage of the glaucoma aqueous shunt market provides detailed analysis of market trends, growth factors, opportunities, challenges, segmentation, regional outlook, and competitive landscape. The study focuses on different glaucoma aqueous shunt types, including valved drainage implants and non-valved drainage implants, along with their growing usage across hospitals, ophthalmology clinics, ambulatory surgery centers, and other healthcare facilities. Nearly 57% of glaucoma surgeries in advanced ophthalmic centers now involve implant-based pressure control procedures, supporting increasing market penetration.

The report also includes SWOT analysis to provide a complete understanding of the market environment. Strength analysis highlights rising adoption of minimally invasive glaucoma surgery procedures, with nearly 49% of ophthalmologists preferring implant-based pressure management systems. Weakness analysis focuses on post-surgical complications and limited specialist availability, affecting around 32% of patients in developing healthcare regions. Opportunity analysis identifies increasing elderly population and growing glaucoma awareness campaigns, with screening programs expanding by approximately 38% worldwide.

Threat analysis covers pricing pressure, healthcare reimbursement limitations, and growing competition among ophthalmic device manufacturers. Around 34% of smaller healthcare facilities still lack access to advanced glaucoma surgery technologies, limiting treatment expansion. The report also evaluates regional market performance, where North America accounts for 38% share, Europe holds 27%, Asia-Pacific contributes 25%, and Middle East & Africa represents 10% share of the global glaucoma aqueous shunt market.

In addition, the report studies technological innovation, healthcare infrastructure growth, patient treatment patterns, and increasing investments in ophthalmology research. Nearly 41% of manufacturers are focusing on advanced biocompatible materials to improve implant performance and reduce complications. The report coverage also examines competitive strategies, product launches, surgical training activities, and partnerships that are shaping the future development of the glaucoma aqueous shunt market.

Future Scope

The future scope of the glaucoma aqueous shunt market remains highly positive due to increasing glaucoma prevalence, rising elderly population, and continuous advancement in ophthalmic surgical technologies. Nearly 54% of eye care specialists expect higher adoption of glaucoma implants because of increasing demand for long-term intraocular pressure management. Expansion of minimally invasive glaucoma surgery procedures is expected to improve treatment accessibility across both developed and developing healthcare systems.

Advanced implant materials are expected to play a major role in future market growth. Around 43% of ongoing ophthalmic device research programs are focused on improving implant flexibility, durability, and fluid control efficiency. Smart glaucoma monitoring systems integrated with digital healthcare platforms are also gaining attention, with adoption expected to increase by approximately 35% among specialty eye hospitals. Improved surgical navigation systems are helping surgeons achieve higher implant accuracy and lower complication rates.

The glaucoma aqueous shunt market is also expected to benefit from increasing outpatient surgical procedures. Nearly 39% of ophthalmology centers are expanding same-day glaucoma surgery services to improve patient convenience and reduce healthcare burden. Pediatric glaucoma treatment is another important growth area, with specialized implant demand increasing by around 23% because of rising awareness regarding early childhood eye disorders.

Emerging healthcare economies are projected to create strong future opportunities as glaucoma screening and diagnosis activities continue to improve. Around 37% of urban healthcare programs are increasing investment in eye disease prevention campaigns and advanced ophthalmology services. Manufacturers are also expected to focus on personalized glaucoma treatment devices and drug-eluting implants to improve long-term surgical outcomes. Increasing collaboration between healthcare providers, ophthalmology researchers, and medical device companies will continue supporting innovation and expansion in the glaucoma aqueous shunt market.

Glaucoma Aqueous Shunt Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1.06 Billion in 2026
Market Size Value By	USD 2.09 Billion by 2035
Growth Rate	CAGR of 6.98% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Valved Drainage Implants Non-valved Drainage Implants By Application : Hospital Ophthalmology Clinics Ambulatory Surgery Centers Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Glaucoma Aqueous Shunt Market expected to touch by 2035?

  The global Glaucoma Aqueous Shunt Market is expected to reach USD 2.09 Billion by 2035.

• What CAGR is the Glaucoma Aqueous Shunt Market expected to exhibit by 2035?

  The Glaucoma Aqueous Shunt Market is expected to exhibit a CAGR of 6.98% by 2035.

• Who are the top players in the Glaucoma Aqueous Shunt Market?

  AbbVie, Santen Pharmaceutical, Johnson and Johnson, Advanced Ophthalmic Innovations (AOI), New World Medical, Glaukos Corp, Ocular Therapeutix, PolyActiva

• What was the value of the Glaucoma Aqueous Shunt Market in 2025?

  In 2025, the Glaucoma Aqueous Shunt Market value stood at USD 1.06 Billion.

Related Reports

Medical ECMO System Market In Vitro Plasma Lipid Adsorption Filter Market Over-the-Counter Veterinary Drugs Market Acyclovir Sodium Injection Market Ferritin Testing Market Childhood Absence Epilepsy Therapeutics Market